Medicinova Inc: (NASD: MNOV)
$2.57
0.07 (2.80%)
Volume 33,784
Jun 18 03:59 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 2.53 - 2.63 |
| 52wk Low - High | 1.49 - 4.70 |
| Previous Close | 2.50 |
| Avg. Volume | 40,526 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 49.17 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.88 |
| P/E (F1) | 0.00 |
| Current Year Est. | -0.54 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
105 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.54 |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -0.56 |
| Expected Earnings Growth | NA |
Company Description
MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | -0.54 | NA |
| Number of Estimates | 0 | 0 | 1 | 0 |
| Low Estimate | NA | NA | -0.54 | NA |
| High Estimate | NA | NA | -0.54 | NA |
| Year Ago EPS | -0.14 | -0.14 | -0.66 | -0.54 |
| EPS Growth | NA | NA | 18.18% | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| MEDICINOVA INC | MNOV | 2.50 | |
|
| AETERNA ZENTARS | AEZS | 1.90 | |
|
| BIOGEN IDEC INC | BIIB | 207.75 | |
|
| MYRIAD GENETICS | MYGN | 26.62 | |
|
| PROTALIX BIOTHR | PLX | 5.04 | |
|
| ADDEX THERA LTD | ADDXF | 3.95 | |
|
| AFFYMAX INC | AFFY | 1.09 | |
|
| ALEXION PHARMA | ALXN | 91.32 | |
|
| ALNYLAM PHARMA | ALNY | 29.69 | |
|
| ANTHERA PHARMA | ANTH | 0.57 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | -0.56 |
| Sales | 1 |
| Net Income | -10 |
| Price/Earnings | NA |
| Price/Book | 3.02 |
| Price/Cash Flow | NA |
| Price/Sales | 79.94 |
News
UCLA Presents Data on MediciNova's MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence - Globenewswire
Jun 18, 2013
UAL, OREX, PLG, DM, AWI, MNOV Are Seasonally Ripe To Go Down In the Next Five Weeks - M2
May 31, 2013
MediciNova Q1 net loss down - Datamonitor
May 22, 2013
Monday Sector Leaders: Biotechnology, Drugs - Marketnewsvideo.Com
May 13, 2013
Morning Market Movers - Benzinga
May 13, 2013
Market Maker Surveillance Report. LPSN, GV, WG, PZZI, KEM, MNOV, Losing Stocks With Lowest Price Friction For Thursday, May 9th 2013 - M2
May 10, 2013
MediciNova Reports First Quarter 2013 Results - Globenewswire
May 8, 2013
The Best Performing Low Risk Stocks of the Year So Far - Kapitall
May 8, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 6.00 |
| Industry Rank by ABR | 105 out of 265 |
| Rank in Industry | 31 out of 153 |
